Literature DB >> 23343193

The dynamic nature of the kinome.

Lee M Graves1, James S Duncan, Martin C Whittle, Gary L Johnson.   

Abstract

Recent advances in proteomics have facilitated the analysis of the kinome 'en masse'. What these studies have revealed is a surprisingly dynamic network of kinase responses to highly selective kinase inhibitors, thereby illustrating the complex biological responses to these small molecules. Moreover these studies have identified key transcription factors, such as c-Myc and FOXO (forkhead box O), that play pivotal roles in kinome reprogramming in cancer cells. Since many kinase inhibitors fail despite a high efficacy of blocking their intended targets, elucidating kinome changes at a more global level will be essential to understanding the mechanisms of kinase inhibitor pharmacology. The development of technologies to study the kinome, as well as examples of kinome resilience and reprogramming, will be discussed in the present review.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343193      PMCID: PMC3808244          DOI: 10.1042/BJ20121456

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  98 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 2.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

3.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

Review 4.  Mechanisms of drug resistance in kinases.

Authors:  Rina Barouch-Bentov; Karsten Sauer
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

Review 5.  Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.

Authors:  Jeremy S Logue; Deborah K Morrison
Journal:  Genes Dev       Date:  2012-04-01       Impact factor: 11.361

6.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

Review 7.  Epidermal growth factor receptor inhibitors in oncology.

Authors:  Igor Vivanco; Ingo K Mellinghoff
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

Review 8.  New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.

Authors:  S Schenone; C Brullo; M Botta
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 9.  ErbB receptors and signaling pathways in cancer.

Authors:  Nancy E Hynes; Gwen MacDonald
Journal:  Curr Opin Cell Biol       Date:  2009-02-07       Impact factor: 8.382

10.  Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF.

Authors:  Rosaura Esteve-Puig; Francesc Canals; Núria Colomé; Glenn Merlino; Juan Angel Recio
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more
  39 in total

1.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

Review 2.  Cell signaling regulation by protein phosphorylation: a multivariate, heterogeneous, and context-dependent process.

Authors:  Evan K Day; Nisha G Sosale; Matthew J Lazzara
Journal:  Curr Opin Biotechnol       Date:  2016-07-06       Impact factor: 9.740

Review 3.  Enigmatic MELK: The controversy surrounding its complex role in cancer.

Authors:  Ian M McDonald; Lee M Graves
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

Review 4.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

5.  Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.

Authors:  Martin L Sos; Rebecca S Levin; John D Gordan; Juan A Oses-Prieto; James T Webber; Megan Salt; Byron Hann; Alma L Burlingame; Frank McCormick; Sourav Bandyopadhyay; Kevan M Shokat
Journal:  Cell Rep       Date:  2014-08-07       Impact factor: 9.423

6.  The butterfly effect in cancer: a single base mutation can remodel the cell.

Authors:  Jonathan R Hart; Yaoyang Zhang; Lujian Liao; Lynn Ueno; Lisa Du; Marloes Jonkers; John R Yates; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

7.  Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival.

Authors:  Brett M Noel; Steven B Ouellette; Laura Marholz; Deborah Dickey; Connor Navis; Tzu-Yi Yang; Vinh Nguyen; Sarah J Parker; David Bernlohr; Zohar Sachs; Laurie L Parker
Journal:  J Proteome Res       Date:  2019-02-21       Impact factor: 4.466

8.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Authors:  George M Burslem; Blake E Smith; Ashton C Lai; Saul Jaime-Figueroa; Daniel C McQuaid; Daniel P Bondeson; Momar Toure; Hanqing Dong; Yimin Qian; Jing Wang; Andrew P Crew; John Hines; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

9.  Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.

Authors:  Alison M Kurimchak; Carlos Herrera-Montávez; Jennifer Brown; Katherine J Johnson; Valerie Sodi; Nishi Srivastava; Vikas Kumar; Safoora Deihimi; Shane O'Brien; Suraj Peri; Gina M Mantia-Smaldone; Angela Jain; Ryan M Winters; Kathy Q Cai; Jonathan Chernoff; Denise C Connolly; James S Duncan
Journal:  Sci Signal       Date:  2020-02-18       Impact factor: 8.192

10.  Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.

Authors:  Alison M Kurimchak; Claude Shelton; Carlos Herrera-Montávez; Kelly E Duncan; Jonathan Chernoff; James S Duncan
Journal:  Mol Cancer Res       Date:  2019-05-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.